---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018272"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:14:36.576179+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma retains Ladenburg Thalmann for strategic options review

## Summary
- Retained Ladenburg Thalmann & Co. Inc. as financial advisor for strategic review.
- Board formed Special Committee in April 2022 to explore value-maximizing alternatives.
- Potential alternatives include acquisition, merger, business combination, or other transaction.
- No timetable set for review; no assurance that any transaction will result.

## SEC filing metadata
- accession: 0001564590-22-018272
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022018272/0001564590-22-018272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022018272/abio-8k_20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018272
- JSON: https://secwatch.observer/filing/0001564590-22-018272.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.